非酒精性脂肪性肝病儿童血清TIMP-1和TIMP-2检测及临床意义

李毓雯; 朱传龙; 高人焘; 潘家华

PDF(979 KB)

中国当代儿科杂志 ›› 2010, Vol. 12 ›› Issue (06) : 455-458.

论著·临床研究

非酒精性脂肪性肝病儿童血清TIMP-1和TIMP-2检测及临床意义

李毓雯，朱传龙，高人焘，潘家华

作者信息 +

Determination and clinical significance of tissue inhibitors of metalloproteinase-1 and -2 in serum of children with nonalcoholic fatty liver disease

LI Yu-Wen, ZHU Chuan-Long, GAO Ren-Tao, PAN Jia-Hua

Author information +

文章历史 +

摘要

目的：了解非酒精性脂肪性肝病患儿基质金属蛋白酶组织抑制物（TIMP）-1和TIMP-2的水平及价值。方法根据诊断标准将105例肥胖儿童分为单纯性肥胖（n=44）、单纯性非酒精性脂肪肝（SNAFL，n=25）和非酒精性脂肪肝炎（NASH，n=36）3组，采用酶联免疫吸附方法(ELISA)测定血清TIMP-1、TIMP-2，全自动酶法测定丙氨酸氨基转移酶(ALT)和γ-谷氨酸转肽酶(γ-GT)。结果随着单纯性肥胖向SNAFL和NASH发展，TIMP-1和γ-GT水平逐步升高，差异有统计学意义(P<0.05)；TIMP-1、TIMP-2两者均与γ-GT水平呈显著正相关(r=0.534,P<0.01；r=0.351,P<0.05)。NASH组TIMP-1阳性率明显高于SNAFL组(P﹤0.05)，而TIMP-2阳性率两组之间差异无统计学意义 (P>0.05)。结论血清TIMP-1和TIMP-2指标均可不同程度地反映肝脏的纤维化程度，其中以TIMP-1更为可靠、有效。［中国当代儿科杂志，2010，12（6）：455-458］

Abstract

OBJECTIVE: To examine serum tissue inhibitors of metalloproteinases (TIMP) -1 and -2 levels in children with nonalcoholic fatty liver disease and to investigate possible roles of the two markers. METHODS: One hundred and five obese children were classified into 4 groups: simple obesity (n=44), simple nonalcoholic fatty liver (SNAFL, n=25), and nonalcoholic steatohepatitis (NASH, n=36). Serum TIMP-1 and -2 levels were measured using ELISA. Serum ALT and γ-GT levels were measured with totally automatic enzymatic method. RESULTS: Serum levels of TIMP-1 and γ-GT increased with the disease development from simple obesity to SNAFL and NASH (P<0.05). Both serum TIMP-1 and -2 levels were positively correlated with γ-GT levels (r=0.534，P<0.01; r=0.351, P<0.05, respectively). Ninety-seven percent of children in the NASH group had serum TIMP-1 levels over 2 standard deviations of healthy controls (83.35 μg/ L) compared with 76% in the SNAFL group (P﹤0.05). There were no significant differences in the case proportion with TIMP-2 levels over 2 standard deviations of healthy controls between the NASH and the SNAFL groups. CONCLUSIONS: Both TIMP-1 and -2 may reflect the state of liver fibrosis in children with nonalcoholic fatty liver disease, and serum TIMP-1 appears to be more reliable.［Chin J Contemp Pediatr, 2010, 12 (6):455-458］

导出引用

李毓雯, 朱传龙, 高人焘, 潘家华. 非酒精性脂肪性肝病儿童血清TIMP-1和TIMP-2检测及临床意义[J]. 中国当代儿科杂志. 2010, 12(06): 455-458

LI Yu-Wen, ZHU Chuan-Long, GAO Ren-Tao, PAN Jia-Hua. Determination and clinical significance of tissue inhibitors of metalloproteinase-1 and -2 in serum of children with nonalcoholic fatty liver disease[J]. Chinese Journal of Contemporary Pediatrics. 2010, 12(06): 455-458

中图分类号： R725 R446.11

参考文献

［1］Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease［J］. Hepatology, 2009, 50(4):1282-1293.
［2］Nie QH, Cheng YQ, Xie YM, Zhou YX, Bai XG, Cao YZ. Methodologic research on TIMP-1, TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance［J］. World J Gastroenterol, 2002, 8(2):282-287.
［3］邵彬，聂青和. 基质金属蛋白酶组织抑制剂(TIMPs)的基础及临床研究现状［J］.实用肝脏病杂志，2005, 8(3):182-186.
［4］季成叶.中国学生超重肥胖BMI筛查标准的应用［J］.中国学校卫生，2004，25(1):125-128．
［5］中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南［J］.中华肝脏病学杂志，2006,14(3):161-163.
［6］Pacifico L, Celestre M, Anania C, Paolantonio P, Chiesa C, Laghi A. MRI and ultrasound for hepatic fat quantification: relationships to clinical and metabolic characteristics of pediatric nonalcoholic fatty liver disease［J］. Acta Paediatr, 2007, 96(4):542-547.
［7］中华医学会传染病学与寄生虫学分会、肝病学分会.慢性乙肝防治指南［J］.中华肝脏病学杂志，2005,13(12):881-891.
［8］Bataller R, Brenner DA. Liver fibrosis［J］.J Clin Invest,2005,115(2):209-218.
［9］滕光菊，聂青和.经皮肝脏活体穿刺活检技巧及研究进展［J］.世界华人消化杂志，2003,11(6):775-776.
［10］聂青和，谢玉梅，周永兴，罗新栋，罗红，程勇前. 毒素型及免疫型大鼠肝纤维化肝组织中金属蛋白酶组织抑制因子定位及表达差异［J］.肝脏，2005,10(2):82-85.
［11］Nie QH, Zhang YF, Xie YM, Luo XD, Shao B, Li J, et al. Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models ［J］. World J Gastroenterol, 2006, 12(19):3044-3049.
［12］Murawaki Y, Ikuta Y, Kawasaki H. Clinical usefulness of serum tissue inhibitor of metalloproteinase (TIMP)-2 assay in patients with chronic liver disease in comparison with serum TIMP-1［J］. Clin Chim Acta, 1999, 281(1-2):109-120.